Key statistics
On Friday, Ultimovacs ASA (ULTI:OSL) closed at 2.16, 37.58% above the 52 week low of 1.57 set on Oct 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.30 |
---|---|
High | 2.33 |
Low | 2.11 |
Bid | 2.16 |
Offer | 2.16 |
Previous close | 2.27 |
Average volume | 439.71k |
---|---|
Shares outstanding | 34.41m |
Free float | 20.67m |
P/E (TTM) | -- |
Market cap | 78.10m NOK |
EPS (TTM) | -4.34 NOK |
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Announcements
- Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update
- Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation
- Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv
- Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
- Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024
- Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
- Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation
- Ultimovacs Announces Notice of Resignation from Deputy Board Member
- Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer
- Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024
More ▼